Trials / Unknown
UnknownNCT05830240
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Head and Neck Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Shanghai Yunying Medical Technology · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
9 participants are expected to be enrolled for this open，single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory head and neck cancer.
Conditions
- Head and Neck Cancer
- Esophageal Cancer
- Otorhinolaryngologic Neoplasms
- Ear Cancer
- Nose Cancer
- Laryngeal Cancer
- Pharyngeal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant oncolytic herpes simplex virus type 1 (R130) | R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11 |
Timeline
- Start date
- 2023-03-27
- Primary completion
- 2025-03-27
- Completion
- 2026-03-27
- First posted
- 2023-04-26
- Last updated
- 2023-04-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05830240. Inclusion in this directory is not an endorsement.